BRINTELLIX (vortioxetine), antidepressant

No clinical benefit demonstrated in the treatment of major depressive episodes by comparison with other antidepressants

• BRINTELLIX has Marketing Authorisation in the treatment of major depressive episodes in adults.

• It is a new alternative to the antidepressants that are currently available. The clinical data (superiority studies versus placebo and non-inferiority study versus comparator) did not demonstrate superiority over the available alternatives.